ACCURAY INC (ARAY): Nasdaq/NYSE listing notice — Accuray receives Nasdaq deficiency notice for bid price below $1; 180-day cure period

ACCURAY INC

Received Nasdaq notice on Feb 2, 2026 for non-compliance with $1 minimum bid price rule.
Has 180-day compliance period until Aug 3, 2026 to regain compliance by closing bid >= $1 for 10 consecutive days.
May be eligible for second 180-day period by transferring to Nasdaq Capital Market if not cured initially.
Common stock continues trading under symbol ARAY while company evaluates options.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ACCURAY INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(H), 5810(c)(3)(A)(i)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(H), 5810(c)(3)(A)(i)

Exact text from the filing

February 2, 2026, the Company received a notice from the Nasdaq Listing Qualifications Department (the “Nasdaq Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price for the last 30 consecutive business days, the Company was no longer in compliance with Nasdaq Listing Rules 5550(a)(2) (the “Bid Price Rule”) which requires listed securities to maintain a minimum bid price of $1 per share. The notification has no immediate effect on the listing of the Company’s common stock, and its common stock will continue to trade on Nasdaq under the symbol “ARAY”

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

ACCURAY INC filing history →

Source: SEC EDGAR

accession 0001437749-26-003367

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.